Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rapport Therapeutics, Inc.

NASDAQ: RAPP · Life Sciences · 15 alerts · CIK 2012593

Share price
$24.82Close, Nov 16
Market cap
$1.47B
Shares outstanding
59.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rapport Therapeutics, Inc. filings on SEC EDGAR ↗

6:06 AM ET 8-K
Clinical Trial Data

Rapport Therapeutics Clinical Trial Data

Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.